Many of us are familiar with THC and CBD. Few of us are well acquainted with their uses as research is still being done worldwide. Those of us who are familiar with CBD are also at least vaguely familiar with decarboxylation—heating CBDA to turn it into “active” CBD. There is common misconception that CBDA is an inert cannabinoid, only made useful once in the form of CBD. Research is showing that this is simply untrue. Producers of CBD are learning of CBDA’s value and beginning to make blended oils that have both CBD and CBDA. But why?
While there are numerous uses that have been speculated about or studied, I have found research that shows CBDA’s potential for fighting breast cancer among others. Takeda et al. (2012) looked at how CBDA affects a particularly invasive breast cancer cell type, MDA-MB-231. The results showed that CBDA stopped cell migration (the way that cancer cells spread). They also noted that this effect would be seen with other cancer types due to the way it acts within the body. While it did not kill the cancer cells, this noted effect is crucial to the prevention of cancer metastasis (spreading throughout the body). With more research showing that CBD and other components of hemp/cannabis can kill cancer or affect it in other important ways, it seems crucial to ensure that CBDA is included in hemp and other cannabis-derived oil products.
Takeda, S., Okajima, S., Miyoshi, H., Yoshida, K., Okamoto, Y., Okada, T., . . .
Omiecinski, C. J. (2012). Cannabidiolic acid, a major cannabinoid in
fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell
migration [PDF]. Toxicology Letters, 214(3), 314-319. https://doi.org/